Cat. No.: X24-08-YM342
Gap junction protein inhibitor, Gap 26, Purity ≥98%
Synonym: 197250-15-0; Gap-26; Gap26; (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-Amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
- MDL: MFCD06411601
- CAS Number: 197250-15-0
- Compound CID: 25088334
Product Size
5 mg; 10 mg; 25 mg; 50 mg
Properties
Description
Gap 26, soluble in DMSO, water and ethanol, is an effective cytoskeleton inhibitor, that has the ability to prevent the pathway of cytoskeletal signaling by inhibiting gap junction protein.
Molecular Formula
C70H107N19O19S
Titer
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects
Solubility
In vitro: DMSO: 93 mg/mL (59.97 mM); Water: 93 mg/mL (59.97 mM); Ethanol: 47 mg/mL
Applications
Gap 26 is a cytoskeletal signaling inhibitor that can be studied extensively for its potential therapeutic applications in the treatment of conditions involving altered gap junction communication, such as cancer and cardiovascular diseases.
Related Products
-
Gap junction protein inhibitor, Tonabersat, Purity ≥98%
-
Gap junction protein inhibitor, Gap 27, Purity ≥98%
-
Gap junction protein inhibitor, GnRH associated peptide (GAP) (1-13), human, Purity ≥98%
-
Gap junction protein inhibitor, 10Panx, Purity ≥98%
-
Gap junction protein inhibitor, Scrambled 10Panx, Purity ≥98%
-
Gap junction protein inhibitor, GAP-134, Purity ≥98%
